MOLECULAR AND GENETIC MARKERS FOR CORONARY HEART DISEASE PROGNOSIS IN ELDERLY PATIENTS

The molecular and genetic markers for primary and secondary prevention of coronary heart disease (CHD) were identified based on the analysis of lipid metabolism gene polymorphisms – lipoprotein lipase (LPL); apolipoprotein E (apoE); and I/D polymorphism of ACE in CHD patients from various age groups, including elderly individuals, and with various clinical variants of CHD (II-III Functional Class stable angina, unstable angina, myocardial infarction (MI), post-infarction cardiosclerosis), as well as in the control group of healthy volunteers. ACE gene DD genotypes, LPL gene H+/+ genotypes, and Е3Е4 increased the MI risk in CHD patients and could be regarded as high-risk markers [4,6-8]. Genotype DD was associated with higher risk of recurrent MI, life-threatening MI complications, and severe heart failure. Moreover, DD genotype was linked to specific personality traits (hostility and Type A behavior), which act as psychological risk factors of CHD and explain delayed medical attendance [2,9]. ApoE gene ε2 allele and LPL gene H allele were observed significantly more often in CHD patients aged over 90 years, compared to younger individuals. Therefore, these alleles could be regarded as the markers of stable clinical CHD course [4].

Coronary heart disease, prognosis, molecular and genetic markers, prevention, elderly age

1. Арутюнов Г.П. Статины и острые коронарные синдромы. Мы на пороге нового стандарта лечения// Клин. фармакол. и терапия. 2001. Т.3, №10:2-7.

2. Вершинин А.А., Мелентьев И.А., Малыгина Н.А. и др. Клиническое течение ишемической болезни сердца и постинфарктное ремоделирование у больных с различными генотипами гена ангиотензинпревращающего фермента // Вестник РГМУ. Периодический медицинский журнал. – М.: РГМУ. – 2006, №3 (50). С.9-15.

3. Демографический ежегодник России. Статистический сборник. Москва. 2002.

4. Костомарова И.В. Молекулярно-генетические маркеры особенностей течения ишемической болезни сердца и продолжительности жизни больных старших возрастных групп Автореферат на соискание ученой степени кандидата медицинских наук, 2002.

5. Кухарчук В. В. – Итоги ХIV Международного конгресса по атеросклерозу // Кардиологический вестник, 2006, т.1, №2: 1-6.

6. Малыгина Н.А., Мелентьев А.С., Костомарова И.В. и др. Связь HindIII ДНК-полиморфимзма гена липопротеинлипазы с продолжительностью жизни больных ишемической болезнью сердца пожилого и старческого возраста // Молекулярная биология, 2001, Т.35, №.5: 787-791.

7. Малыгина Н. А., Костомарова И. В., Дерягин Г.В. и др. HindIII ДНК-полиморфизм гена липопротеин липазы у больных с ишемической болезнью сердца пожилого возраста // Терапевтический архив, 2002, № 2, стр. 64-66.

8. Малыгина Н.А., Костомарова И.В., Мелентьев А.С.и др. Связь I/D полиморфизма гена ангиотензинпревращающего фермента с наследственной предрасположенностью к инфаркту миокарда и прогнозу течения ИБС у больных пожилого возраста // Клиническая медицинf, 2002, т. 80, №8: 25-29.

9. Мелентьев И.А, Вершинин А.А., Колесникова Е.А. и др. Полиморфизм гена АПФ: аспекты клиники и психогенетики личностно-поведенческих факторов риска ИБС // Вестник РГМУ, 2006. №6 53. 7-13.

10. Сайгитов Р.Т. Острый коронарный сидром: клинико-генетические аспекты прогнозирования и профилактики. Автореферат диссертации на соискание ученой степени д.м.н. 2007, С. 47.

11. Чазов Е.И. Ишемическая болезнь сердца, инфаркт миокарда, атеросклероз. 1992. Москва, с.178

12. Шулутко Б.И. Артериальная гипертензия. СПб.: Гиппократ, 2001. C.382.

13. The World Health Report 2003e. Geneva, Switzerland: World Health Organization; 2003. Available on-line at: http://www.who.int/whr/2003/ en/Annex2-en.pdf.

14. Anderson J.L., King G.J., Bair T.L. et al. Association of lipoprotein lipase gene polymorphism with coronary artery disease // J Am Coll Cardiol. 1999; 15; 33(4): 1013-1020.

15. Atzmon G, Rincon M., Schechter C. B et. al. Lipoprotein Genotype and Conserved Pathway for Exceptional Longevity in Humans.//PLOS biology. 2006, v.4: 1-18.

16. Barzilai N, Atzmon G., Schechter C. et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity// JAMA. 2003; v. 290, 15: 2030-40.

17. Bessenyei B, M. Marka, L. Urban, M. et al. Single nucleotide polymorphisms: aging and diseases. Review article // Biogerontology. 2004; 5: 291-303.

18. Bladbjerg E.M., Andersen-Ranberg K., de Maat M.P. et al. Longevity is independent of common variations in genes associated with cardiovascular risk // Thromb Haemost, 1999, v.82, №3:1100-5.

19. Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects // Circulation. 2005; 25; 111(3):278-87.

20. Cambien F., Poirier O., Lecerf L. et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction // Nature. 1992; 359: 641-644

21. Chuang L.M., Chiu K.C., Chiang F.T., et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with hypertension, non-insulin-dependent diabetes mellitus, and coronary heart disease in Taiwan // Metabolism. 1997; оct 46(10): 1211-14.

22. Dawber T.R. Incidence of coronary heart disease, stroke and peripheral arterial disease in the Framingham Study: the Epidemiology of Atherosclerotic Disease. Cambridge, M. A., Harvard University Press, 1980: 59-75.

23. Gambino R., Scaglione L., Alemanno N., Pagano G., Cassader M. Human lipoprotein lipase HindIII polymorphism in young patients with myocardial infarction // Metabolism. 1999; 48(9): 1157-61

24. De Grooth GJ, Klerkx AH, Stroes ES. et al. A review of CETP and its relation to atherosclerosis // J Lipid Res. 2004; v. 45, (11): 1967-74.

25. Humphries S.E., Nicaud V., Margalef J. et.al. The European Atherosclerosis Research Study (EARS) Lipoprotein lipase gene variation is association with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides // Arterioscler Thromb Vasc Biol. 1998; 18: 526-34.

26. Ilveskoski E., Perola M., Lehtimaki T. et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study // Circulation 1999;100(6):608-613.

27. Klos K.L., Hamon S., Clark A.G., et al. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study // J Lipid Res. 2005; Mar;46(3): 564-71. E

28. Kuivenhoven J. A, Kastelein J.P. Polymorphism of the cholesteryl-ester transfer protein gene// N Engl J Med. 1998; 338: 1625-6.

29. Lee W.J., Sheu W.H.., Jeng C.Y. et al. Associations between lipoprotein lipase gene polymorphisms and insulin resistance in coronary heart disease // Chung Hua I Hsueh Tsa Chih (Taipei). 2000; 63(7): 563-72.

30. Lehtimaki T., Moilanen T., Solakivi T., et al. Cholesterol-rich diet induced changes in plasma lipids in relation to apolipoprotein E phenotype in healthy students// Ann Med. 1992;24:61-66.

31. МсKusick V. A. On-line Mendelian Inheritance in Man (OMIM)⎯ 2008.

32. Ordovas J.M.., Cupples L.A., Corella D. et al. Association of cholesteryl ester transfer protein – TaqIB polymorfism with variations in lipopotein subclasses and coronary heart disease risk // Arteroscler. Thromb.Vasc. Biol. 2000; 20: 1323-44.

33. Schachter F., Faure-Delanef L., Guenot F. et al. Genetic association with human longevity at the APOE and ACE loci // Nature Genetic. 1994; 6: 29-32.

34. Tiret L., Knijf P., Menzel H.-J. et.al. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study//Arterioscler thromb 1994;14:1617-1624. 35. Wilson P.W.F., William H.W., Castelli W.P. et al. Coronary risk predition in adults (The Framingham Study) // Am J Cardiol. 1987; 59: 1-94.